The Silver Lining of the COVID-19 Pandemic: Fast-Tracked Vaccine Production and Approval

Author:

Lewis Mandala Wilson

Abstract

From the time when the smallpox vaccine was successfully produced in 1798, vaccines have proven to be the most reliable means for preventing and controlling most infectious diseases because they significantly reduce morbidity and mortality associated with life-threatening infectious diseases. During the pre-COVID-19 era, the development, testing, and final approval for vaccines would take as long as thirty years and this was regarded as a normal procedure by most regulatory bodies. However, the devastating COVID-19 pandemic witnessed the development and approval of several vaccines in just six months from when the first SARS-CoV-2 case was reported in Wuhan, China. The speed and apparent ease with which the COVID-19 vaccines have been produced and approved has introduced a paradigm shift in the vaccinology field, creating an environment within which the production of vaccines for most infectious disease now seems possible. This chapter delves into the vaccine production and approval process and discusses the benefits of vaccines, the types of vaccines, and how they work. It also explores how lessons from the COVID-19 pandemic can contribute toward the expedited development, trial, and approval of vaccines against other devastating diseases of equally high, if not higher, mortality rates such as HIV/AIDS, TB, and malaria.

Publisher

IntechOpen

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3